Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
15.82
-0.58 (-3.54%)
Jan 9, 2026, 4:00 PM EST - Market closed
Amarin Corporation Employees
Amarin Corporation had 275 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
275
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$824,484
Profits / Employee
-$313,425
Market Cap
328.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275 | 0 | - |
| Dec 31, 2023 | 275 | -90 | -24.66% |
| Dec 31, 2022 | 365 | -195 | -34.82% |
| Dec 31, 2021 | 560 | -440 | -44.00% |
| Dec 31, 2020 | 1,000 | 35 | 3.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AMRN News
- 2 days ago - Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization - GlobeNewsWire
- 2 months ago - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients - GlobeNewsWire
- 2 months ago - Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 2 months ago - Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewsWire
- 3 months ago - Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom - Seeking Alpha
- 4 months ago - Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 - GlobeNewsWire
- 4 months ago - New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups - GlobeNewsWire